This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Fresh with a new brand identity, the France-headquartered pharma group has pledged to grow its oncology sales from its current objective of €1 billion in 2025 to €3 billion in 2030, continuing a diversification of its business from its traditional focus on cardiovascular diseases. billion and $1.8 billion, respectively, five years later.
India, synonymous with the “pharmacy of the world” has rightfully earned the title, owing to its remarkable contribution in supplying 20 per cent of the global genericmedicines, along with 60 per cent of the total vaccine demand worldwide. Concurrently, the Indian pharma segment has witnessed steady growth with a CAGR of 9.43
Encouraging Competition : The FDA should work to lift barriers to generic drug competition by addressing scientific and regulatory obstacles. This can help increase the availability of lower-cost, genericmedicines and reduce the cost burden on patients and the healthcare system. References Schulman, K. JAMA, 314(14), 14691470.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
98 
Let's personalize your content